Sarcoidosis has exactly two FDA-approved medicines, and one of them dates to 1952. Everything else in real-world use is technically off-label, borrowed from other diseases because nothing purpose-built has come along. That's not a sign that nothing is happening, it's a sign that a lot of the most interesting activity right now is happening in repurposed drugs and small studies rather than in a pipeline of sarcoidosis-specific medicines. Here's what that actually looks like.
Looking for treatment options for Sarcoidosis?
Browse open Sarcoidosis clinical trials near you! We'll handle the follow-up.
What's approved right now, in plain terms
Oral corticosteroids are the default first-line treatment. They calm the immune activity driving granuloma formation broadly, but long-term or high-dose use carries real side effects, weight gain, bone thinning, mood changes, and more, which is a major reason so much current research focuses on steroid-sparing alternatives.
Repository corticotropin injection is the other approved option, used mainly when steroids alone aren't enough or aren't tolerated. It works through a different hormonal pathway and has shown steroid-sparing benefit in some patients, though it's generally considered a second-line option given cost and more limited evidence compared to steroids.
The repurposed drug getting real attention
Tofacitinib, a JAK inhibitor already approved for rheumatoid arthritis and several other autoimmune conditions, has become one of the more closely watched off-label options for sarcoidosis that hasn't responded to standard treatment. The idea traces back to a single detailed case report published in 2018, followed by a small Yale-led open-label study of 10 patients with sarcoidosis affecting the skin (and in most cases, the lungs too) who hadn't improved on other therapies.
Skin disease responded particularly well, and several patients were able to stop methotrexate entirely. A separate case report described tofacitinib preventing a life-threatening airway complication in a patient with severe laryngeal sarcoidosis who had run out of other options. This remains small-study, off-label evidence, not the result of a large randomized trial, but it's a genuinely active area researchers are pushing to study further.
A therapy that already disappointed
TNF inhibitors, a class of biologic already used for rheumatoid arthritis, psoriasis, and other inflammatory diseases, were once seen as a promising steroid-sparing option for sarcoidosis given how they work in similar diseases. In controlled trials, though, the benefit turned out to be marginal at best, and in some cases TNF inhibitors have actually triggered or worsened sarcoidosis in people being treated for a different condition. It's a useful reminder that drugs which work well for one inflammatory disease don't automatically transfer to another that looks superficially similar.
What researchers are studying now
Beyond tofacitinib, current research includes non-steroid approaches aimed at the specific inflammatory pathways thought to drive granuloma formation, rather than suppressing the immune system broadly the way steroids do. The goal across most of this research is the same: find something that controls the disease as well as steroids do, without the long-term cost of staying on steroids for years.
Why sarcoidosis research is unusually hard
The repurposing-first problem. Because no sarcoidosis-specific drug pipeline exists the way it does for many other diseases, most promising leads start as "this worked for a different disease, might it work here too" rather than a purpose-built sarcoidosis program, which tends to mean smaller, slower, case-report-driven evidence before anyone commits to a large trial.
The false-lead problem. TNF inhibitors looked like an obvious next step based on how similar diseases responded, and it didn't pan out that way, which makes researchers appropriately more cautious about assuming any single "similar disease, similar drug" idea will work before it's actually tested.
The remission-versus-treatment problem. Because roughly two thirds of sarcoidosis resolves on its own within a few years, trials have to work hard to enroll people whose disease is genuinely likely to need ongoing treatment, rather than people who might have improved on their own regardless of what they were given.
How sarcoidosis actually gets diagnosed
There's no single blood test that confirms sarcoidosis. Diagnosis typically combines imaging (a chest X-ray or CT scan showing a characteristic pattern), a biopsy showing the specific type of inflammation under a microscope, and ruling out other conditions that can look similar, including infections like tuberculosis, which can present in a strikingly similar way on imaging. This is part of why sarcoidosis sometimes takes a while to pin down, it's confirmed by a specific pattern plus a process of elimination, not one definitive test.
Common myths, cleared up
"Sarcoidosis is contagious, since it involves inflammation and can look like an infection on scans."
It's not. It's often confused with tuberculosis on imaging specifically because both can cause similar-looking lymph node swelling, but sarcoidosis is not caused by a germ and cannot be passed to another person.
"If steroids work, that means it's a mild case."
Steroid response doesn't map neatly onto severity; some serious, multi-organ cases respond well to steroids, while some milder-seeming skin or lymph node cases can be surprisingly steroid-resistant.
"A repurposed drug is a lesser option than something 'designed' for the disease."
Repurposed drugs like tofacitinib are being studied because they target a biological pathway that's genuinely relevant to sarcoidosis, not as a fallback; several widely used medicines across many diseases started as repurposed treatments from something else entirely.
How to find a sarcoidosis study through our platform
Search current studies by which organs are affected for you and whether you're looking for a steroid-sparing option specifically, since eligibility and study goals differ a lot along those lines. Right now, for example, you can find a Phase 2 study testing rilonacept, a non-steroid anti-inflammatory approach, in people with cardiac sarcoidosis, as well as a broader patient registry tracking sarcoidosis outcomes over time for anyone ages 7 and up. Our sarcoidosis clinical trials page always shows the current live count of recruiting studies. Applying takes about 5 minutes, and a coordinator follows up to confirm fit.
Common questions
What are the symptoms of sarcoidosis? Symptoms depend heavily on which organs are involved, but common ones include a persistent cough, shortness of breath, fatigue, swollen lymph nodes, and skin bumps or rashes. Many people have no symptoms at all and are only diagnosed after an unrelated chest X-ray shows something unexpected.
Is sarcoidosis genetic? Having a close relative with sarcoidosis raises your own risk somewhat, and researchers have identified genes linked to it, but most cases occur in people with no family history at all. It's thought to involve a combination of genetic susceptibility and some kind of environmental trigger that hasn't been fully identified.
Is there a cure for sarcoidosis? Not currently. Many cases resolve on their own within a few years without ever needing a cure, but for the smaller group whose disease becomes chronic, treatment manages symptoms and limits organ damage rather than eliminating the disease.
What triggers a sarcoidosis flare-up? There's no single known trigger, and flares can happen without any clear cause. Some people report flares tied to stress, infections, or reduced steroid doses, but this varies a lot from person to person, and there's no reliable way to predict them.
Are there stages of sarcoidosis? Lung involvement is sometimes classified into four stages based on chest X-ray findings, ranging from normal-looking lungs with just enlarged lymph nodes to more advanced scarring. These stages describe what shows up on imaging, not how severe someone's symptoms feel day to day.